Efficacy of a novel idiotypic antibody to inhibit cholesterol retention in atherosclerotic vascular disease during insulin resistance and diabetes.

新型独特型抗体在胰岛素抵抗和糖尿病期间抑制动脉粥样硬化性血管疾病中胆固醇滞留的功效。

• 批准号: 389516
• 负责人: Proctor Spencer D
• 金额: $ 40.4万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-09-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=389516&lang=en
• 关键词: Animal Models; Arterial Retention; Atherosclerosis; Chimeric Antibodies; Glycosaminoglycans; Human Derived Specimens; Idiotypic Antibodies; Remnant Lipoproteins

Excess fat (cholesterol) deposits in our blood vessels can lead to heart disease. The blood vessel wall is made up of special proteins that contain sugar molecules with sticky regions that specifically attach and trap the cholesterol-carrying particles ci

过多的脂肪（胆固醇）沉积在我们的血管中会导致心脏病。血管壁是由特殊的蛋白质组成的，这些蛋白质含有糖分子，糖分子具有粘性区域，这些粘性区域专门附着并捕获携带胆固醇的颗粒ci。